Products & Tech | Page 42 of 63

Insulin Therapy Improves Blood Sugar Control in Type 2 Diabetes Patients With Few Hypoglycemic Occurrences

Data from the A1chieve® study, evaluating adverse events and effectiveness of Novo Nordisk insulins (NovoMix 30, Levemir and NovoRapid) in 66,726 people with type 2 diabetes, shows that type 2 diabetes patients can significantly improve their blood glucose control with a low occurrence of low blood sugar (hypoglycemia)...

Why Type 2 Diabetes Patients Resist Intensifying Insulin Treatment, Lilly to Conduct Study

Eli Lilly has announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles (MOSA1c study) that people with type 2 diabetes face which prevent them from reaching their ultimate treatment goals...

Effortless Diabetes Logging: A Review of Glooko

Glooko is a cable that connects iPhones, iPods and iPads to a variety of different glucose meters and automatically downloads blood glucose readings, eliminating the need for you to manually write down records.

Type 2 Diabetes Drug ONGLYZA Approved for Sale in Europe

The European Commission has approved Bristol-Myers Squibb Company and AstraZeneca's ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycemic) control in adult patients with type 2 diabetes...

Insulin Like A String of Pearls: How Degludec Works

There was one thing about Degludec that caught my attention, and after speaking to Dr. Alan Moses of Novo Nordisk about it, I now believe Degludec is awesome.

Little Things We’re Grateful For

It's almost Thanksgiving, the time of year when we, like many others, focus on how grateful we are for the good things in life. Mike and I are incredibly grateful for the life we share and for the family we've created together. Diabetes does take a toll on us, but overall we're doing okay. We're not complaining.

Disappointing Results for GSK’s New Type 2 Diabetes Drug Albiglutide (Tanzeum)

Results showed a reduction in HbA1c of 0.78% for patients receiving albiglutide compared to a reduction of 0.99% for liraglutide. While albiglutide did demonstrate a statistically significant reduction in HbA1c from baseline (p<0.001), it did not meet the pre-specified primary endpoint of non-inferiority to liraglutide...

FDA Clears PositiveID’s iglucose, A Wireless Communication Diabetes Management System

The U.S. Food and Drug Administration (FDA) granted PositiveID Corporation clearance for its iglucose(TM) mobile health system for diabetes management. iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating glucose readings from data-capable glucometers to the iglucose diabetes management portal, this important data can be shared with family members, caregivers and healthcare professionals...

FDA approves the t:slim, Tandem Diabetes Care Innovative Insulin Pump

The U.S. Food and Drug Administration (FDA) has granted Tandem Diabetes Care clearance to market the t:slim™ Insulin Delivery System (t:slim). This new full-featured pump is the first-ever with a color touch screen, and is the smallest insulin pump system currently available. The t:slim is one of the first insulin pumps to be cleared under the FDA’s new Infusion Pump Improvement Initiative...

FDA Grants Medtronic Approval to Conduct In-Home Study of Insulin Pump with Low Glucose Suspend

The U.S. Food and Drug Administration (FDA) has given Medtronic approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE (Automation to Simulate Pancreatic InsulinREsponse) study of the MiniMed Paradigm® System featuring Low Glucose Suspend (LGS) automation. FDA approval of the IDE makes Medtronic’s ASPIRE study the first in-home pivotal trial of a closed loop system for type 1 diabetes management...